Terapia Intensiva
Revisão sobre as complicações vasculares na COVID-19.
2 Nov, 2021 | 12:34hRevisão | Cetamina para tratamento de dor aguda.
2 Nov, 2021 | 12:16hKetamine for the treatment of acute pain – Canadian Medical Association Journal
Comentário no Twitter
If you manage pain in hospital, low-dose ketamine should be in your toolkit. And not just in the ED.
Quick overview with @WKSilverstein & @JonZipursky in @CMAJ: https://t.co/w5h3vIMiEK pic.twitter.com/gVO7W9dcYY
— David Juurlink (@DavidJuurlink) November 1, 2021
Estudo de coorte | Entre pacientes com infarto do miocárdio com elevação do segmento ST, o diagnóstico concomitante de Covid-19 está associado a aumento de mortalidade intra-hospitalar.
1 Nov, 2021 | 11:01hEditorial: Myocardial Infarction During the COVID-19 Pandemic – JAMA
Comentário: STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet – TCTMD
Comentário do autor no Twitter (fio – clique para saber mais)
1/8 It was not unexpected that pts w/ #STEMI would fare worse w/ than w/o #COVID19 https://t.co/B7oWnJunEa
— Herb Aronow, MD, MPH (he/him/his) (@herbaronowMD) October 29, 2021
Revisão | Como abordar um paciente com bacteriemia por Staphylococcus aureus resistente à meticilina.
1 Nov, 2021 | 10:50hHow I manage a patient with MRSA bacteraemia – Clinical Microbiology and Infection
Complicações da COVID-19 crítica: considerações terapêuticas e diagnósticas para o paciente sob ventilação mecânica.
29 Out, 2021 | 14:51h
Diretriz AHA/ACC 2021 para avaliação e diagnóstico de dor torácica.
29 Out, 2021 | 14:49hResumo executivo: 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain – Journal of the American College of Cardiology
Comunicado de imprensa: First-Ever Guideline Focused Solely on Chest Pain Evaluation, Diagnosis Released
Foco da diretriz: Guideline for the Evaluation and Diagnosis of Chest Pain
Pontos principais: 2021 AHA/ACC Chest Pain Guideline – American College of Cardiology
Comentário: New Chest Pain Guidelines Out at Last: Most Tests Have a Role – TCTMD
Comentário no Twitter (fio – clique para saber mais)
The Chest Pain Guidelines are now released!https://t.co/xQxCWzReEN
Top 10: CHEST PAINS
Thanks to the entire writing group and my co-cahirs: Deb Murkerjee & Phil Levy
💥First Chest Pain Guidelines @AHAScience @ACCinTouch pic.twitter.com/s17piamrKR— Dr. Martha Gulati “Get Vaccinated Please” (@DrMarthaGulati) October 28, 2021
Lesão cerebral após parada cardíaca: fisiopatologia, tratamento e prognóstico.
29 Out, 2021 | 14:35h
Comentário no Twitter
Post-cardiac arrest brain injury, narrative review:
🧠pathophysiology: primary (ischemic) & secondary (reperfusion)
🧠treatment options
🧠outcomes
🧠neuroprognostication
🧠@ERC_resus @ESICM 2021 algorithm for prognostication
Open #FOAMcc #FOAMres @yourICM https://t.co/b8GRhE3MuF pic.twitter.com/q10DJVRJOp— Intens Care Med (@yourICM) October 27, 2021
Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.
28 Out, 2021 | 16:22hComentários:
The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM
The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews
Conteúdos relacionados:
Comentário no Twitter
NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY
— The Lancet (@TheLancet) October 27, 2021
Estudo randomizado | Tratamento precoce da Covid-19 com sotrovimabe (anticorpo neutralizante do SARS-CoV-2) está associado a risco reduzido de internação.
28 Out, 2021 | 16:18h
Comentário no Twitter
In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB
— NEJM (@NEJM) October 27, 2021
Subfenótipos longitudinais respiratórios em pacientes com síndrome da angústia respiratória aguda associada a COVID-19: resultados de 3 estudos de coorte observacionais.
28 Out, 2021 | 16:10hComentários:
Respiratory Subphenotypes of COVID-19-Related ARDS – ICU Management & Practice
Comentário no Twitter
NEW—At baseline, #COVID19-related #ARDS has no consistent resp subphenotype. Pts diverged from fairly homogenous to a more heterogeneous popn, w/ trajectories of ventilatory ratio and mechanical power being the most discriminatory.
PRoVENT–COVID study: https://t.co/v8GTVcYLxq pic.twitter.com/Tv72jOzuAC
— The Lancet Respiratory Medicine (@LancetRespirMed) October 13, 2021